Artist’s rendering of a light purple Ebola virus looping around itself that’s surrounded by red blood cells
Ebola Lurking in Brain Fluid Kills Monkeys Weeks After Recovery
New research reveals where the virus was hiding and hints at how to truly purge it from the body.
ABOVE: © ISTOCK.COM, DR_MICROBE
Ebola Lurking in Brain Fluid Kills Monkeys Weeks After Recovery
Ebola Lurking in Brain Fluid Kills Monkeys Weeks After Recovery

New research reveals where the virus was hiding and hints at how to truly purge it from the body.

New research reveals where the virus was hiding and hints at how to truly purge it from the body.

ABOVE: © ISTOCK.COM, DR_MICROBE

monoclonal antibodies

Updated
Merck research facility in San Francisco
Antiviral Pill Lowers Risks of COVID-19 Hospitalization, Death
Chloe Tenn | Oct 1, 2021
Merck reports that its antiviral molnupiravir was effective against early stages of COVID-19 in high-risk patients in a Phase 3 clinical trial.
Updated
blue and white sign for the entrance to the FDA that says U.S. Department of Health and Human Services Food and Drug Administration
Biogen’s Alzheimer’s Drug Gets FDA Approval, Mixed Reviews
Kerry Grens | Jun 7, 2021
A lackluster performance in clinical trials of the monoclonal antibody aducanumab has left some experts unconvinced of its benefit.
Molecular Farming: The Future of Pharmaceuticals
The Scientist Speaks - Molecular Farming: The Future of Pharmaceuticals
Niki Spahich, PhD | Nov 16, 2021
Julian Ma discusses past, present, and future uses of plant biotechnology for disease treatments.
A microscopy image of a mouse brain that shows the lymphatic system in bright purple and pink
Brain’s Lymphatic System Tied to Alzheimer’s Symptoms in Mice
Amanda Heidt | May 4, 2021
A dysfunctional lymphatic system, described as a clogging of the brain’s sink, may explain why immunotherapies fail in some Alzheimer’s patients.
regeneron monoclonal antibody sars-cov-2 covid-19 pandemic coronavirus neutralization b.1.351 variant south africa REGN10987 casirivimab and REGN10933 imdevimab
Regeneron Cocktail Stumbles Against SARS-CoV-2 Variant in Vitro
Marcus A. Banks | Mar 1, 2021
A treatment of two monoclonal antibodies against SARS-CoV-2 is ninefold less effective in the lab against the B.1.351 variant than against the dominant version of the virus.
Identifying Antibodies that Target Membrane Proteins in Their Native Conformations
The Scientist Creative Services Team in collaboration with OXGENE | May 10, 2021
A new mammalian display platform enhances antibody discovery for challenging protein targets.
Eli Lilly Halts Antibody Trial in Hospitalized COVID-19 Patients
Ashley Yeager | Oct 27, 2020
Recent data show that the drug bamlanivimab, also known as LY-CoV555, does not appear to help those with severe cases of COVID-19, but trials continue for milder cases.
Antibody-Based Drug May Reduce COVID-19 Hospitalizations: Study
Lisa Winter | Sep 17, 2020
Eli Lilly reports a 72 percent reduction in hospitalization risk among patients who received its monoclonal antibody compared to those who received a placebo.
Technique Talk: Analyzing Molecular Interactions During Monoclonal Antibody Development
The Scientist Creative Services Team in collaboration with Sartorius Corporation | Mar 9, 2021
In this workshop, you will learn how to measure protein interactions using Octet bio-layer interferometry.
Bacterial Superglue Enables Antiviral Antibody Discovery
Ruth Williams | Jul 13, 2020
Testing out combinations of antiviral proteins from llamas could help researchers create potent virus-neutralizing multimers.
monoclonal antibody antibodies sars-cov-2 covid-19 coronavirus pandemic eli lilly receptor binding domain spike protein
First Antibody Trial Launched in COVID-19 Patients
Katarina Zimmer | Jun 2, 2020
In record time, scientists have gone from harvesting antibodies against SARS-CoV-2 from survivors of coronavirus infections to testing the antibodies’ safety as a drug in humans.
A Greener Recombinant Monoclonal Antibody
The Scientist Creative Services Team | Dec 9, 2020
Learn more about environmentally-friendly antibodies that deliver superior performance.
coronavirus sars-cov-2 spike protein covid-19 structure glycans ace2 furin antibody
Scientists Scan for Weaknesses in the SARS-CoV-2 Spike Protein
Chris Baraniuk | Apr 9, 2020
The virus’s tool for prying open host cells is coated in a protective armor of sugar—but gaps may offer vulnerability to disruption by antibodies.
UCB Cuts $2.1 Billion Deal to Acquire Ra Pharma
Catherine Offord | Oct 14, 2019
The move will allow the Belgium-headquartered biopharmaceutical giant to boost its work on treatments for rare diseases.
Putting the Brakes on SARS-CoV-2: Neutralizing Antibodies
The Scientist Creative Services Team | Jul 6, 2020
Experts will discuss potential neutralizing antibodies currently under investigation for SARS-CoV-2 treatment.
Two Experimental Drugs Effective at Treating Ebola
Catherine Offord | Aug 13, 2019
REGN-EB3 and mAb114 reduced mortality in a clinical trial carried out during the ongoing outbreak in Democratic Republic of Congo.
MIT Researcher Allegedly Copied Other Groups’ Drug Designs
Catherine Offord | May 29, 2019
Executives at a biotech that develops new antibodies argue that Ram Sasisekharan didn’t come up with the structures for at least two experimental therapies that his group has described.
John Mendelsohn, Former MD Anderson Cancer Center President, Dies
Ashley Yeager | Jan 10, 2019
The scientist and clinician helped develop a new form of cancer therapy, using a monoclonal antibody to treat head, neck, colorectal, and lung cancers.
Ebola Clinical Trial to Begin Amid Outbreak in DRC
Ashley P. Taylor | Nov 12, 2018
The study will examine the efficacy of four drugs—an antiviral and three monoclonal antibodies—that are already being used to treat patients in Democratic Republic of Congo.